Therapeutic options in relapsed or refractory peripheral T-cell lymphoma  by Coiffier, Bertrand et al.
Cancer Treatment Reviews 40 (2014) 1080–1088Contents lists available at ScienceDirect
Cancer Treatment Reviews
journal homepage: www.elsevierheal th.com/ journals /c t rvAnti-Tumour TreatmentTherapeutic options in relapsed or refractory peripheral T-cell
lymphomahttp://dx.doi.org/10.1016/j.ctrv.2014.08.001
0305-7372/ 2014 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
⇑ Corresponding author. Tel.: +33 478864302; fax: +33 78864355.
E-mail addresses: bertrand.coifﬁer@univ-lyon1.fr (B. Coifﬁer), massimo.federico
@unimore.it (M. Federico), cabarri@usal.es (D. Caballero), claire.dearden@rmh.
nhs.uk (C. Dearden), franck.morschhauser@chru-lille.fr (F. Morschhauser), ulrich.
jaeger@meduniwien.ac.at (U. Jäger), lorenz.truemper@med.uni-goettingen.de
(L. Trümper), emanuele.zucca@eoc.ch (E. Zucca), mgsilva@ipolisboa.min-saude.pt
(M. Gomes da Silva), r.pettengell@sgul.ac.uk (R. Pettengell), weidmann.eckhart@
khnw.de (E. Weidmann), frandamo@rm.dk (F. d’Amore), herve.tilly@rouen.fnclcc.fr
(H. Tilly), pierluigi.zinzani@unibo.it (P.L. Zinzani).Bertrand Coifﬁer a,⇑, Massimo Federico b, Dolores Caballero c, Claire Dearden d, Franck Morschhauser e,
Ulrich Jäger f, Lorenz Trümper g, Emanuele Zucca h, Maria Gomes da Silva i, Ruth Pettengell j,
Eckhart Weidmann k, Francesco d’Amore l, Hervé Tillym, Pier Luigi Zinzani n
aUniversity of Lyon 1, 17 Rue de France, 69627 Lyon, France
bDipartimento di Medicina di Laboratorio, Clinica e di Sanità Pubblica, Università degli studi di Modena e Reggio Emilia, Policlinico, Via del Pozzo, 71, 41124 Modena, Italy
c Instituto Biosanitario de Salamanca, Paseo de San Vicente 58-182, 37007 Salamanca, Spain
dDepartment of Haemato-Oncology, Royal Marsden Hospital, Downs Road, SM2 5PT Sutton, UK
eDepartment of Hematology, University Hospital of Lille, F-59037 Lille, France
fMedical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Comprehensive Cancer Center, Waehringer Guertel 18-20, 1090 Vienna, Austria
gUniversitätsKrebszentrum (G-CCC), Georg August University, 37099 Göttingen, Germany
hOncology Institute of Southern Switzerland (IOSI), Ospedale San Giovanni, 6500 Bellinzona, Switzerland
i Instituto Português de Oncologia de Lisboa de Francisco Gentil, R. Prof. Lima Basto, 1099-023 Lisbon, Portugal
j St George’s University of London, Cranmer Terrace, London SW17 0RE, UK
kKlinik für Onkologie und Hämatologie am Krankenhaus Nordwest GmbH, Steinbacher Hohl 2-26, D-60488 Frankfurt, Germany
lDepartment Hematology, Aarhus University Hospital, Tage Hansens Gade 2, DK-8000 Aarhus C, Denmark
mDepartment of Hematology, Centre Henri-Becquerel, UMR918, Université de Rouen, Rue d’Amiens, 76038 Rouen Cedex 1, France
n Institute of Hematology ‘‘Seràgnoli’’, University of Bologna, Via Massarenti 9, 40138 Bologna, Italya r t i c l e i n f o
Article history:
Received 21 August 2013
Received in revised form 29 July 2014
Accepted 14 August 2014
Keywords:
Peripheral T-cell lymphoma
Histone deacetylase inhibitor
Antifolate
Nucleoside analog
Fusion protein
Immunomodulatory agenta b s t r a c t
Peripheral T-cell lymphoma (PTCL) represents a relatively rare group of heterogeneous non-Hodgkin lym-
phomas with a very poor prognosis. Current therapies, based on historical regimens for aggressive B-cell
lymphomas, have resulted in insufﬁcient patient outcomes. The majority of patients relapse rapidly, and
current 5-year overall survival rates are only 10–30%. It is evident that new approaches to treat patients
with PTCL are required. In recent years, prospective studies in PTCL have been initiated, mainly in
patients with relapsed/refractory disease. In some of these, selected histologic subtypes have been eval-
uated in detail. As a consequence, numerous new therapies have been developed and shown activity in
PTCL, including: agents targeting the immune system (e.g. brentuximab vedotin, alemtuzumab, lenalid-
omide); histone deacetylase inhibitors (romidepsin, belinostat); antifolates (pralatrexate); fusion pro-
teins (denileukin diftitox); nucleoside analogs (pentostatin, gemcitabine); and other agents (e.g.
alisertib, plitidepsin, bendamustine, bortezomib). A variety of interesting novel combinations is also
emerging. It is hoped that these innovative approaches, coupled with a greater understanding of the clin-
icopathologic features, pathogenesis, molecular biology, and natural history of PTCL will advance the ﬁeld
and improve outcomes in this challenging group of diseases. This review summarizes the currently avail-
able clinical evidence on the various approaches to treating relapsed/refractory PTCL, including the role of
stem cell transplantation, with an emphasis on potential new drug therapies.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Peripheral T-cell lymphoma (PTCL), a subset of non-Hodgkin
lymphoma (NHL), comprises a spectrum of rare and usually
aggressive T-cell disorders with a generally poor prognosis. The
2008 World Health Organization classiﬁcation system contains
22 biologically and clinically different T-cell lymphoma subgroups,
further subclassiﬁed as nodal, extranodal, cutaneous, or leukemic,
which are distinct with respect to pathology, clinical presentation,
Table 1
Incidence and 5-year OS across PTCL subtypes [2].
Diagnosis Incidence
(%)
5-Year
OS (%)
PTCL-NOS 25.9 32
AITL 18.5 32
NKTCL 10.4
Nasal 42
Extra-nasal 9
ATLL 9.6 14
ALK-positive ALCL 6.6 70
ALK-negative ALCL 5.5 49
Enteropathy-type T-cell lymphoma 4.7 20
Primary cutaneous ALCL 1.7 90
Hepatosplenic T-cell lymphoma 1.4 7
Subcutaneous panniculitis-like-T-cell lymphoma 0.9 64
AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large-cell lymphoma;
ALK, anaplastic lymphoma kinase; ATLL, adult T-cell leukemia/lymphoma; NKTCL,
natural killer/T-cell lymphoma; OS, overall survival; PTCL-NOS, peripheral T-cell
lymphoma-not otherwise speciﬁed.
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most common subgroups are PTCL-not otherwise speciﬁed
(PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), adult
T-cell leukemia/lymphoma (ATLL), and anaplastic large-cell lym-
phoma (ALCL) (Table 1) [2].
The treatment approach of PTCL has traditionally been similar
to diffuse large B-cell lymphoma (DLBCL); however, outcomes
are poor when PTCL is treated according to paradigms established
for aggressive B-cell lymphomas [3]. Due to its rarity and the het-
erogeneity of subtypes, randomized controlled trials comparing
different treatment approaches for PTCL are limited. Standard
ﬁrst-line therapy consists of CHOP (cyclophosphamide, doxorubi-
cin, vincristine, and prednisone) or a CHOP-like regimen. Thera-
peutic responses to this approach have been neither adequate
nor durable, with rapid relapse in some subtypes [4,5]. Data col-
lected by the International T-Cell Lymphoma Project over the past
decade on over 1314 cases of PTCL revealed that survival rates
were highly dependent upon disease subtype, with poor 5-year
overall survival (OS) rates for most subtypes: 32% for PTCL-NOS
and AITL, 49% for anaplastic lymphoma kinase (ALK)-negative
ALCL, and 14% for ATLL (Table 1) [2]. Indeed, PTCL-NOS patients
with multiple risk factors have been reported to have 5-year OS
rates as low as 11% [6]. In general, the 5-year OS of PTCL patients
is reported to be signiﬁcantly lower than aggressive B-cell lym-
phoma patients (41% versus 53%; p = 0.0004) [7].
Some phase II trials suggest that intensiﬁcation with autologous
stem cell transplantation (ASCT) could improve treatment out-
comes, especially when patients are in ﬁrst complete response
(CR). However, many patients are not candidates for stem cell
transplantation (SCT) because they do not reach stable remission
after induction therapy—approximately 30% of the patients will
progress before ASCT [8–10].
The generally poor outcomes observed in PTCL patients high-
light the urgent need for alternative treatment strategies. Several
novel approaches have been evaluated in single-arm phase I and
II studies, mainly in patients with relapsed/refractory disease,
who have a particularly poor prognosis. This review summarizes
the currently available clinical evidence on the various approaches
for treating relapsed/refractory PTCL, with an emphasis on poten-
tial new drug therapies.
New treatment modalities
Recent research has led to the development of numerous
agents, including: immunoconjugates, immunotherapies, and
immunomodulators; histone deacetylase (HDAC) inhibitors; anti-
folates; fusion proteins; and nucleoside analogs (Table 2) [11–37].Immunoconjugates, immunotherapies, and immunomodulators
Anti-CD30 antibodies
Hodgkin lymphoma and ALCL are the most common CD30-
expressing tumors [38]. However, monoclonal antibodies that tar-
get CD30, including MDX-060 [39], and SGN-30 [40,41], have
shown minimal clinical activity.
Brentuximab vedotin (SGN-35) is an antibody–drug conjugate
that links an anti-CD30 antibody to a potent antimicrotubule
agent, monomethylauristatin E (MMAE), enabling the delivery of
the cytotoxic drug to the target malignant cell. Binding of MMAE
to tubulin disrupts the microtubule network, induces cell-cycle
arrest, and results in apoptotic death of the CD30-expressing
tumor cell [42]. A phase II study of brentuximab vedotin in 58
patients with ALCL showed an overall response rate (ORR) of
86%, including 57% CRs, with a median duration of response
(DoR) of 12.6 months (Table 2) [17]. The most common (P30%)
adverse events (AEs) were peripheral sensory neuropathy (41%),
nausea (40%), fatigue (38%), and pyrexia (34%). AEs led to treat-
ment discontinuation in 24% of patients. Based on the results of
this study, the US Food and Drug Administration (FDA) and Euro-
pean Medicines Agency approved the use of brentuximab vedotin
for patients with systemic ALCL after failure of P1 multi-agent
chemotherapy regimen. Another phase II trial of brentuximab
vedotin in 34 patients with PTCL showed an ORR of 41% with a
median progression-free survival (PFS) of 2.6 months (Table 2)
[18].
Alemtuzumab
The anti-CD52 monoclonal antibody alemtuzumab has been
evaluated in two small phase II studies (Table 2) [11,12]. In the ﬁrst
study, 14 patients with PTCL received alemtuzumab (dose rapidly
escalated to 30 mg) three-times-weekly for a maximum of
12 weeks [11], with an ORR of 36%. However, 10 patients discon-
tinued treatment due to AEs or progressive disease; 5 patients
experienced cytomegalovirus (CMV) reactivation after a median
of 5 weeks. In a pilot study of 10 patients with PTCL-NOS or myco-
sis fungoides (MF) using a reduced-dose-intensity approach
(10 mg three-times-weekly for 4 weeks), an ORR of 60% with a
median DoR of 7 months was reported [12]. Fewer AEs and CMV
reactivations were found; infusion-related AEs occurred in 3
patients (30%) and CMV reactivation in 1 patient (10%) [12]. Two
phase III front-line trials were expected to ﬁnish recruitment at
the end of 2013, and favorable safety data have been reported so
far [43].
Mogamulizumab
Mogamulizumab is a monoclonal antibody targeting CC chemo-
kine receptor 4 (CCR4). A phase II study of weekly 1.0 mg/kg
mogamulizumab infusions in 27 patients with relapsed, aggressive
CCR4+ T-cell lymphoma showed an ORR of 50%, including 31% CR
(Table 2) [25]. Median PFS was 5.2 months and median OS was
13.7 months. The most common (P15%) grade 3–4 AEs were lym-
phopenia (74%), leukocytopenia (30%), thrombocytopenia (19%),
neutropenia (19%), and rash (19%). Another phase II study of
mogamulizumab at the same dose in 38 patients (of which 37 were
evaluable) with relapsed CCR4+ PTCL or cutaneous T cell lym-
phoma (CTCL) showed an ORR of 35%, including 14% CR (Table 2);
median PFS was 3 months [26]. The most common (P15%) grade
3–4 AEs were lymphocytopenia (73%) and neutropenia (19%).
Zanolimumab
The anti-CD4 monoclonal antibody zanolimumab was studied
in a phase II study including 21 PTCL patients (Table 2) [37].
Weekly zanolimumab 980 mg infusions produced an ORR of 24%
and 10% CR with no major toxicity. Five drug-related grade 3 AEs
Table 2
Clinical trial efﬁcacy results of novel single-agent treatment modalities.
Drug/regimen Study No. of evaluable
patients
Type of patients ORR (%) Median DoR
(months)
Median PFS
(months)
Alemtuzumab Enblad (2004) [11] 14 PTCL 36 NR NR
Zinzani (2005) [12] 10 PTCL-NOS and MF 60 7 NR
Alisertib Friedberg (2014) [13] 48 NHL (including PTCL) 27 NR NR
Belinostat O’Connor (2013) [14] 120 PTCL 26 8.3 NR
Bendamustine Damaj (2013) [15] 60 PTCL and CTCL 50 3.5 3.6
Bortezomib Zinzani (2007) [16] 12 PTCL and CTCL 67 NR NR
Brentuximab vedotin Pro (2012) [17] 58 ALCL 86 12.6 13.3
Horwitz (2014) [18] 34 PTCL 41 7.6 2.6
Denileukin diftitox Dang (2007) [19] 27 PTCL 48 NR 6
Gemcitabine Zinzani (1998) [20] 13 PTCL-NOS and MF 69 NR NR
Sallah (2001) [21] 10 PTCL-NOS and CTCL 60 13.5 NR
Zinzani (2010) [22] 39 PTCL-NOS and MF 51 NR NR
Lenalidomide Dueck (2010) [23] 23 PTCL 30 NR 3.2
Zinzani (2011) [24] 10 PTCL-NOS 30 NR NR
Mogamulizumab Ishida (2012) [25] 26 ATLL 50 NR 5.2
Ogura (2014) [26] 37 CCR4+ PTCL/CTCL 35 NR 3.0
Pentostatin Monfardini (1996) [27] 37 NHL (including PTCL) 13 8 NR
Tsimberidou (2004) [28] 44 T-cell leukemias/lymphomas 55 4.3 2.1
Dang (2003) [29] 14 T-cell NHL 50 NR 6
Plitidepsin Ribrag (2013) [30] 29 PTCL 21 2.2 1.6
Pralatrexate aO’Connor (2009) [31] 29 T-cell lymphoma 54 NR NR
O’Connor (2011) [32] 109 PTCL 29 10.1 3.5
Romidepsin Piekarz (2011) [33] 45 PTCL and CTCL 38 8.9 NR
Coifﬁer (2012) [34]
(2014) [35]
130 PTCL 25 28 4
Tipifarnib Witzig (2011) [36] 93 NHL (including PTCL) 20 (50 in
PTCL-NOS)
7.5 NR
Zanolimumab d’Amore (2010) [37] 21 PTCL 24 NR NR
ALCL, anaplastic large-cell lymphoma; ATLL, adult T-cell leukemia/lymphoma; CCR4+, CC chemokine receptor 4; CTCL, cutaneous T-cell lymphoma; DoR, duration of response;
MF, mycosis fungoides; NHL, non-Hodgkin lymphoma; NOS, not otherwise speciﬁed; NR, not reported; ORR, overall response rate; PFS, progression-free survival; PTCL,
peripheral T-cell lymphoma.
a All studies were phase II, except for this phase I/II study.
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arthralgia (5%) [37].
Lenalidomide
The immunomodulatory drug lenalidomide (25 mg on days 1–
21 of each 28-day cycle) has shown efﬁcacy in patients with
relapsed/refractory PTCL (Table 2) [23,24,44]. A phase II study with
23 evaluable patients showed an ORR of 30% (all partial responses
[PRs]) [23]. The median PFS and OS were 3.2 and 7.9 months,
respectively. AEs were consistent with the known safety proﬁle
of lenalidomide: the most common grade 3–4 AEs (P15%) were
thrombocytopenia (42%), neutropenia (21%), dyspnea (17%), febrile
neutropenia (17%), pain (17%), and pneumonitis (17%). Study dis-
continuation was mainly for progressive disease (PD; 46%); 4
patients (17%) discontinued due to AEs. A subsequent open-label
phase II study in 10 patients with PTCL-NOS also found an ORR
of 30% (all CRs) [24]. The most common grade 3–4 AEs (P15%)
included neutropenia (25%) and thrombocytopenia (15%). The mul-
ticenter, phase II EXPECT trial included 54 relapsed/refractory PTCL
patients, mostly with AITL (n = 26; 48%) and PTCL-NOS (n = 20;
37%) [44]. The ORR was 22% (11% CR/unconﬁrmed CR [CRu]), 31%
(15% CR/CRu) in AITL, and 20% in PTCL-NOS patients. The median
PFS and DoR were 2.5 and 3.6 months, respectively. The most com-
mon grade 3–4 AEs (P15%) included thrombocytopenia (20%), gas-
trointestinal disorders (17%), neutropenia (15%), infections (15%),
and general disorders and administration site conditions (15%).Histone deacetylase inhibitors
Histone deacetylase (HDAC) inhibitors induce histone acetyla-
tion leading to increased expression of tumor suppressor genes.
HDAC inhibition results in cell-cycle arrest, cell differentiation,and apoptosis [45,46]. In vitro and ex vivo studies have reported
synergy with targeted therapies (e.g. CD25-targeted therapy), radi-
ation therapy, and chemotherapy [47–49].Romidepsin
Romidepsin (FK228; previously depsipeptide), an HDAC inhibi-
tor isolated from Chromobacterium violaceum [50,51], is currently
approved by the US FDA for the treatment of PTCL in patients
who have received P1 prior therapy. In a phase II study of romi-
depsin (14 mg/m2 administered as a 4-h infusion on days 1, 8,
and 15 of a 28-day cycle) in separate cohorts of CTCL and relapsed
PTCL patients, the ORR among the 45 PTCL patients was 38%, with
18% CR. Median DoR was 8.9 months; median duration of CR was
29.7 months. The most common (P40%) AEs included nausea
(51%), fatigue (40%), thrombocytopenia (47%), leukopenia (47%),
granulocytopenia (45%), and anemia (40%) (Table 2) [33].
In a subsequent pivotal phase II trial, 130 patients with histo-
logically conﬁrmed relapsed/refractory PTCL were treated with
romidepsin at the same dose for 6 cycles; patients with at least sta-
ble disease (SD) were allowed to continue until PD (Table 2)
[34,35]. Fifty patients (38%) were treated for P4 cycles and 36
patients (28%) received > 6 cycles. Most patients had PTCL-NOS
(n = 69), AITL (n = 27), or ALK-negative ALCL (n = 21). The ORR
was relatively high (25%) considering that these patients had failed
P1 prior therapies; 19 patients (15%) had CR, 10 of which had
long-term (P12 months) response. At a median follow-up of
22.3 months, responders received a median of 8 treatment cycles
(range < 1–54); patients with CR/CRu received a median of 19
treatment cycles (range 2–54). Romidepsin demonstrated clini-
cally meaningful disease control in half of the patients. Similar
CR/CRu rates were observed across the three major PTCL subtypes.
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patients who achieved CR/CRu median, PFS was 29 months and
OS was not reached. The most common (P15%) gradeP3 AEs were
thrombocytopenia (24%), neutropenia (20%), and infections (19%).
Discontinuation of therapy occurred in 19% of patients, mostly
due to thrombocytopenia and pneumonia.
Belinostat
Belinostat is a potent hydroxamic acid-derived pan-HDAC
inhibitor [52] that is currently evaluated in an open-label phase
II study. A total of 129 relapsed/refractory PTCL patients received
a 1000 mg/m2 belinostat infusion on days 1–5 of every 3-week
cycle (Table 2) [14]. Among 120 evaluable patients, the ORR was
26%, including 10% CR, and median DoR was 8.3 months. The most
common (P10%) grade 3–4 AEs were thrombocytopenia (13%),
neutropenia (13%), and anemia (10%). Patients mainly discontin-
ued due to PD (64%); 7% of patients discontinued due to AEs.
Antifolates
Folates are essential for DNA synthesis in any cell, including
cancer cells. In the 1940s it was discovered that antifolates can
be effective in cancer therapy. Currently, antifolates—including
methotrexate—play an important role in the treatment of many
types of cancers [53].
Pralatrexate
Pralatrexate is FDA approved for use in relapsed/refractory
PTCL. The drug is a novel antifolate designed to selectively accu-
mulate in malignant cells and block the biosynthesis of purines
and pyrimidines. In an initial phase I/II study with 29 T-cell lym-
phoma patients, the ORR was 54%, with 31% CR and 23% PR
(Table 2) [31]. In the pivotal phase II PROPEL study, 115 patients
who progressed after P1 prior therapy received pralatrexate
weekly for 6 weeks of each 7-week cycle (Table 2) [32]. Most
patients had PTCL-NOS (n = 59), although a signiﬁcant proportion
had systemic ALCL (n = 17) or AITL (n = 13). Among 109 evaluable
patients, the ORR was 29%, including 11% CR/CRu, and the median
DoR was 10.1 months. A low ORR (8%) was observed in AITL
patients. The most common (P15%) grade 3–4 AEs were thrombo-
cytopenia (32%), neutropenia (22%), mucositis (22%), and anemia
(18%); 71% of patients experienced some degree of mucositis. A
total of 23% of patients discontinued pralatrexate due to AEs,
mostly due to mucositis (6%) and thrombocytopenia (5%).
Fusion proteins
Fusion proteins are engineered to act as decoy receptors,
increase the deliverability of an active substance into the cell,
add stability, recruit immune effector cells, etc.; several fusion pro-
teins are under investigation in oncology [54].
Denileukin diftitox
Denileukin diftitox is a fusion protein comprised of interleukin
(IL)-2 and diphtheria toxin. It selectively targets IL-2 receptor-
expressing cells, where the diphtheria toxin component inhibits
protein synthesis leading to apoptosis. Denileukin diftitox is indi-
cated for the treatment of persistent or recurrent CTCL expressing
the CD25 component of the IL-2 receptor; it is no longer used in pre-
cursor T-cell lymphoblastic leukemia. A phase II study of 27 patients
with relapsed/refractory PTCL showed single-agent activity at a
dose of 18 lg/kg/day (Table 2) with an ORR of 48% (13 patients; 6CRs and 7 PRs) and median PFS of 6 months [19]. Patients with
CD25+ disease had a higher response rate than those with CD25
disease (62% versus 46%, respectively) [19]. The most common
(P50%) AEs were hypoalbuminemia (74%), transaminase elevation
(74%), edema (63%), and skin reactions (59%); no hematologic AEs
were observed and no responders discontinued treatment due to
toxicity. Denileukin diﬁtox in combination with CHOP is currently
studied as ﬁrst-line treatment for patients with PTCL [55].
Nucleoside analogs
Purine nucleoside analogs are cytotoxic agents with strong
immunosuppressive and antineoplastic activity. These agents are
cytotoxic to both proliferating and non-proliferating cells, inhibit-
ing DNA synthesis and repair, and inducing apoptosis [56].
Pentostatin
Three phase II studies have evaluated the antimetabolite pento-
statin in PTCL (Table 2) [27–29]. An early trial studied pentostatin
at an initial dose of 4 mg/m2 weekly for 3 weeks, then every
2 weeks for 6 weeks, and thereafter every 4 weeks, leading to a
low ORR of 13% in 37 patients with B- and T-cell NHL, including
PTCL [27].
Two subsequent studies investigated pentostatin at a dose of
3.75–5.0 mg/m2 over 3 days every 3 or 4 weeks in T-cell NHL,
and reported higher response rates [28,29]. Tsimberidou and col-
leagues reported an ORR of 55% with a median DoR of 4.3 months
[28]. The most common (> 20%) AEs were infections (48%), granu-
locytopenia (36%), and fever (26%); no responders discontinued
treatment because of toxicity. Dang and colleagues reported an
ORR of 50% and a median PFS for responders of 6 months [29].
The most common (> 20%) AEs were fatigue (40%), fever, nausea,
and edema (33% each); 1 patient discontinued the study due to
AEs (severe nausea and vomiting).
In a 10-year retrospective analysis of 145 patients with PTCL
treated with pentostatin, an ORR of 32% was reported [57].
Response rates were highest in patients with Sezary syndrome
(62%) and prolymphocytic leukemia (45%), and were relatively
low in patients with PTCL (19%).
Gemcitabine
Three phase II studies evaluated single-agent gemcitabine in T-
cell lymphoma [20–22], mainly including patients with PTCL-NOS
and MF (Table 2). Gemcitabine 1200 mg/m2 was administered on
days 1, 8, and 15 of a 28-day schedule for 3–6 cycles. ORRs in all
patients ranged from 51–69%, with CR rates in PTCL-NOS patients
ranging from 13–30%. Only one study speciﬁed the median DoR:
13.5 months [21]. In all three studies, gemcitabine was well toler-
ated and AEs were generally mild (grade 1–2) and manageable;
more severe AEs included neutropenic fever requiring dose reduc-
tions in 2 of 10 patients [21] and a grade 3 transient increase of
liver enzymes in 1 of 39 patients [22]. Gemcitabine is now sug-
gested as monotherapy in the treatment of relapsed/refractory
PTCL [58] and has been incorporated into several combination che-
motherapy regimens (see following section).
Other agents
Alisertib
Aurora A kinase (AAK) plays a role in cell proliferation and is
overexpressed in aggressive lymphoma; increased AAK levels are
associated with a poorer prognosis [13]. Alisertib (MLN8237) is a
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twice daily on days 1–7 of each 21-day cycle) was conducted in 48
patients with relapsed/refractory aggressive NHL, including 8
patients with PTCL [13]. ORR was 27% in all patients and 50% in
patients with PTCL. The sample size in this study was small; a
phase III study of alisertib versus investigator’s choice treatment
in patients with relapsed/refractory PTCL is currently recruiting.
Plitidepsin (aplidin)
Plitidepsin, a cyclic depsipeptide isolated from the marine tuni-
cate Aplidium albicans, displays a broad spectrum of antitumor
activities, inducing apoptosis (through induction of early oxidative
stress and activation of the Jun N-terminal kinase pathway), and
G1 and G2 cell-cycle arrest. A phase II study assessed the effects
of plitidepsin (3.2 mg/m2 administered as a 1-h infusion on days
1, 8, and 15 every 4 weeks), in 34 patients with non-cutaneous
PTCL (Table 2) [30]. Of the 29 evaluable patients, 6 responded
(ORR 21%), including 2 CRs and 4 PRs; 6 patients had SD. Notably,
3 of 6 responders had AITL. The median DoR was 2.2 months; 1
patient achieved a long-term remission lasting for 28 months.
The most common (P20%) plitidepsin-related AEs were nausea
(34%; all grade 1–2), fatigue (25%; grade 4 in 2%), and myalgia
(22%; grade 3 in 2%). Severe laboratory abnormalities (mainly
myelosuppression and increased liver transaminase levels) were
transient and manageable; none resulted in treatment
discontinuation.
Bendamustine
Bendamustine is an alkylating agent with antimetabolite prop-
erties that exhibits activity in several hematologic malignancies
and solid tumors. In a recently reported phase II study, 60 patients
with PTCL and CTCL (mainly AITL and PTCL-NOS) were treated with
bendamustine 120 mg/m2 infusions on days 1 and 2 every 3 weeks,
for 6 cycles (Table 2) [15]. The ORR was 50% and the median DoR
was 3.5 months, with 30% of responses lasting > 6 months. The
most frequent (P5%) grade 3–4 AEs were neutropenia (30%),
thrombocytopenia (24%), and infections (20%); infections and
hematologic AEs lead to discontinuation in 5 patients (8%).
Bortezomib
Bortezomib is a proteasome inhibitor with demonstrated activ-
ity in other hematologic malignancies, such as multiple myeloma
and mantle cell lymphoma. In a small (n = 15) phase II study in
CTCL and PTCL patients, bortezomib (1.3 mg/m2 intravenously on
days 1, 4, 8, and 11, every 21 days for a total of 6 cycles) produced
an ORR of 67%, including 1 patient with PTCL-NOS who achieved
CR (Table 2) [16]. Grade 3 AEs comprised neutropenia (17%),
thrombocytopenia (17%), and sensory neuropathy (8%); no grade
4 AEs occurred.
Tipifarnib
Based on preclinical studies demonstrating induction of apopto-
sis in malignant lymphoid cells, the farnesyltransferase inhibitor
tipifarnib (300 mg twice daily on days 1–21 of every 28-day cycle)
was evaluated in a phase II study of 93 patients with a broad spec-
trum of hematologic malignancies, including PTCL (Table 2) [36].
The ORR was 20% in the total population and 50% (4 of 8 patients)
in those with PTCL-NOS, including 3 CRs. Overall, the median DoR
was 7.5 months and median time to progression was 3.6 months.
The most common (P15%) grade 3–4 AEs were neutropenia
(37%) and thrombocytopenia (32%).Combination therapies
Several combination regimens have been evaluated in the treat-
ment of PTCL, including conventional platinum-based regimens
such as dexamethasone, high-dose cytosine arabinoside (Ara-C),
and cisplatin (DHAP); etoposide, methylprednisolone, high-dose
Ara-C, and cisplatin (ESHAP); ifosfamide, carboplatin, and etopo-
side (ICE); gemcitabine-based regimens (with or without platinum
agents); and other non-platinum-containing combinations. Multi-
agent regimens are generally associated with more toxicity than
single-agent approaches and, in the absence of randomized con-
trolled trials, it is unclear whether these regimens are more effec-
tive than single-agent therapies in the treatment of patients with
PTCL.
Platinum-based regimens
Conventional platinum-based regimens, such as DHAP, ESHAP,
and ICE, have been studied in PTCL and are suggested by the
National Comprehensive Cancer Network guidelines as salvage
treatment options after ﬁrst relapse [58].
Response rates are relatively high with DHAP and ESHAP (55%
and 64%, respectively), at the expense of poor tolerability [59,60].
With DHAP, the major toxicities included severe neutropenia
(53%), severe thrombocytopenia (39%), sepsis (31%), rise in serum
creatinine of more than twice the baseline value (20%), and severe
gastrointestinal toxicity (20%) [59]. With ESHAP, the primary AEs
were neutropenic fever requiring admission (30%), rise in serum
creatinine of more than twice the baseline value (22%), and grade
3 nausea/vomiting (8%) [60].
Carboplatin, included in the ICE regimen, is generally better tol-
erated than cisplatin, included in the DHAP and ESHAP regimens. A
response rate of 72% was reported with the ICE regimen in a series
of prospective clinical trials including a total of 222 patients [61].
Most of these patients (n = 176) were diagnosed with DLBCL; 26
were diagnosed with PTCL. The ORR among PTCL patients was
54%, including 8 CRs and 6 PRs, and the 5-year PFS rate was 29%.
Gemcitabine-based regimens
The combination of gemcitabine, dexamethasone, and cisplatin
in relapsed/refractory lymphoma, including T-cell NHL, was evalu-
ated in a phase I study with 22 patients [62]. Gemcitabine (800 mg/
m2) and cisplatin (35 mg/m2) were administered on days 1 and 15
of a 28-day cycle, along with dexamethasone (20 mg/day) for
4 days. Dose escalation of gemcitabine was not possible due to
poor tolerability; the ORR was 45%, including 1 CR and 1 PR in
the 5 evaluable T-cell NHL patients. The GEM-P combination of
gemcitabine (1000 mg/m2 on days 1, 8, and 15), cisplatin
(100 mg/m2 on day 15), and methylprednisolone (1000 mg on days
1–5) every 28 days in PTCL patients was associated with an ORR of
69%, accompanied by high rates of grade 3–4 neutropenia and leu-
kopenia (62% each) [63]. An open-label study, combining gemcita-
bine (1000 mg/m2) with vinorelbine (25 mg/m2) on days 1 and 8 of
each 21-day cycle in 40 patients with relapsed/refractory lym-
phoma, produced an ORR of 53% in the total population and 70%
in the 10 PTCL patients, including 4 CRs (40%) [64]. The most com-
mon (P20%) non-hematologic AEs were fatigue (21% of cycles) and
phlebitis (20% of cycles); grade 4 thrombocytopenia and neutrope-
nia occurred in 15% and 13% of patients, respectively.
L-Asparaginase-based regimens
The enzyme L-asparaginase hydrolyses asparagine, leading to
anticancer effects in lymphoma cells that lack L-asparagine
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retrospective study of 45 patients with relapsed/refractory extran-
odal NKTCL (nasal type) treated with L-asparaginase-based ther-
apy, the response rate was 82% and the 5-year survival rate was
67% [65]. In another retrospective study of 15 patients with
relapsed/refractory or disseminated extranodal NKTCL treated
with L-asparaginase-based regimens, the response rate was 87%,
with 33% (n = 5) of patients alive without disease recurrence after
a median follow-up of 1322 days (approximately 3.5 years) [66].
The combination of L-asparaginase, methotrexate, and dexa-
methasone was evaluated in a prospective phase II study of 18
patients with extranodal NKTCL (nasal type) [67]. The high ORR
(78%) and median DoR (12 months) were offset by the high inci-
dence of grade 3–4 AEs, including neutropenia (42%), anemia
(21%), hepatic AEs (16%), febrile neutropenia (11%), and infections
(11%).
Results from a recent phase II study indicated that the SMILE
regimen (steroid [dexamethasone], methotrexate, ifosfamide,
L-asparaginase, and etoposide) was active in patients with
extranodal NKTCL (nasal type) [68]. Of the 38 patients evaluated,
71% with stage III or IV disease, 20 received SMILE as ﬁrst-line ther-
apy and 18 had relapsed/refractory disease. The ORR was 79% and
did not differ signiﬁcantly between ﬁrst-line and relapsed/refrac-
tory patients. The PFS and OS rates at 1-year were 53% and 55%,
respectively. Hematologic toxicities were common; grade 4 neu-
tropenia and leukopenia occurred in 92% and 76% of patients,
respectively. A total of 61% of patients developed a grade 4 infec-
tion; 10 patients (26%) did not complete the planned treatment,
including 6 patients who discontinued due to AEs.
Interferon and retinoids
Recombinant interferons have previously demonstrated antitu-
mor activity in several types of malignant lymphoma, and retinoids
have shown efﬁcacy in CTCL and a PTCL pilot study. The combina-
tion of interferon-alfa (3 mega units/day) and isotretinoin (1 mg/
kg/day) was assessed in a phase II study of 54 patients, including
6 with PTCL-NOS, 1 with human T-cell leukemia virus (HTLV)-
ATLL, and 1 with ALCL [69]. The response rate was 39% in all
patients and 67% in PTCL-NOS patients, including 3 CRs (50%);
the patients with HTLV-ATLL and ALCL both achieved PR. The most
common (P50%) AEs were ﬂu-like syndrome (91%), fever (91%),
dry skin (57%), fatigue (55%), and hypertriglyceridemia (50%).
Topoisomerase inhibitors
The topoisomerase inhibitors irinotecan and mitoxantrone are
both under evaluation for the treatment of solid tumors and
NHL. After showing signs of efﬁcacy in a small pilot study in
relapsed/refractory NHL patients, the CMD combination of irino-
tecan (25 mg/m2 on days 1 and 2), mitoxantrone (8 mg/m2 on
day 3), and dexamethasone (40 mg/day on days 1–3), administered
every 3 weeks for 6 cycles, was assessed in a phase II study of 30
patients with relapsed/refractory PTCL [70]. The ORR was 60%, with
37% CR; 3-year PFS and OS were 18% and 28%, respectively. Grade
3–4 hematologic AEs were observed in 60% of patients, mostly
grade 4 neutropenia (27%) and grade 3–4 thrombocytopenia
(17%). The only grade P3 non-hematologic AE was febrile neutro-
penia (27%).
CHOP-based regimens
Several trials are assessing if the addition of a novel agent, such
as romidepsin, denileukin diftitox, alemtuzumab, or bortezomib,
can enhance the efﬁcacy of CHOP as ﬁrst-line therapy [71]. Adetailed discussion of ﬁrst-line CHOP-based regimens is beyond
the scope of this review.Other combinations
Few trials have assessed the combination of novel agents with
established chemotherapy regimens in relapsed/refractory
patients. In a recent study, 24 patients with relapsed/refractory
PTCL received alemtuzumab plus DHAP (A-DHAP), with responders
subsequently undergoing ASCT [72]. The ORR was 50%, including 5
CRs. Median OS was 6 months and the median DoR was
2.9 months. The most common AE was grade 3–4 leukopenia
(79%).Stem cell transplantation
Treatment guidelines for PTCL in the US and the UK include SCT
as a treatment option for patients in ﬁrst remission [58,73]. How-
ever, the role of SCT in relapsed/refractory PTCL is unclear. A com-
prehensive discussion of SCT is beyond the scope of this review;
recent reviews by Reimer [74], Schmitz and colleagues [75], and
Hosing and Champlin [76] have explored the role of SCT in patients
with PTCL in more detail.Autologous stem cell transplantation
Evidence exists for the use of ASCT in transplant-eligible
patients with previously untreated PTCL [77–79]. However, initial
studies evaluating ASCT in relapsed/refractory PTCL patients were
disappointing, particularly in patients with ALK-negative disease
[80,81].
The Grupo Español de Linfomas/Trasplante Autólogo de Médula
Ósea (GEL-TAMO) registry of 115 patients with untreated and
relapsed/refractory PTCL treated with ASCT showed 5-year dis-
ease-free survival and OS rates of 60% and 56%, respectively [82].
The authors concluded that results with salvage ASCT in PTCL are
similar to those in aggressive B-cell lymphoma.
In a retrospective analysis assessing the efﬁcacy of ASCT in 53
patients with PTCL, median PFS and OS in the 10 evaluable refrac-
tory patients were 0.3 and 0.8 years, respectively [83]. The investi-
gators concluded that ASCT may be beneﬁcial when used as
consolidation therapy following ﬁrst response, but has minimal
durable beneﬁt in patients with relapsed/refractory PTCL [83].
When outcomes in 36 patients with chemosensitive relapsed PTCL
undergoing ASCT were compared with those from a similar, histor-
ical control group of 97 patients with DLBCL, 3-year event-free sur-
vival rates were not signiﬁcantly different (37% versus 42%) [84].
In AITL, ASCT has been recommended as consolidation therapy
for suitable patients with chemosensitive relapse; it appears to
have limited efﬁcacy in patients with refractory disease [85].
Among 76 patients with AITL who underwent ASCT as salvage
therapy, 4-year PFS rates for patients with chemosensitive
(n = 56) and chemorefractory disease (n = 20) were 30% and 23%,
respectively [85].Allogeneic stem cell transplantation and reduced-intensity
conditioning
After allogeneic SCT, a signiﬁcant, immune-mediated, graft-ver-
sus-lymphoma antitumor effect has been observed in T-cell lym-
phomas, suggesting that allogeneic SCT may be effective in this
setting [86,87]. A retrospective study of allogeneic SCT in
relapsed/refractory PTCL patients demonstrated PFS and OS rates
of 40% and 50% at 5 years, respectively [88].
1086 B. Coifﬁer et al. / Cancer Treatment Reviews 40 (2014) 1080–1088The high treatment-related mortality rates (around 30%) associ-
ated with the use of standard-intensity conditioning have been
attributed primarily to the advanced age of patients with
relapsed/refractory PTCL and to the effects of prior therapy
[87,89]. Therefore, reduced-intensity conditioning with allogeneic
SCT was examined [86,88,90,91].
A phase II study of reduced-intensity conditioning with alloge-
neic SCT in 17 patients with relapsed/refractory PTCL showed
3-year OS and PFS rates of 81% and 64%, respectively, with low
treatment-related mortality (non-relapse mortality probability at
2 years: 6%) [86].
In a study of 10 patients with relapsed PTCL who received
alemtuzumab-based induction therapy, followed by reduced-
intensity ﬂudarabine, busulfan, and cyclophosphamide condition-
ing with allogeneic SCT, 6 patients achieved remission; however,
extensive graft-versus-host disease was observed in 5 of the 10
patients [90].Conclusions
Current patient outcomes suggest the need for novel regimens
and alternative strategies to improve disease management and
extend the duration of response. New compounds with novel
mechanisms of action, such as the ones described in this review,
may help to improve patient outcomes. Treatment can be individ-
ualized based on the histopathologic PTCL subtype, and regimens
can be tailored to patient characteristics. Furthermore, biomarkers
should be further explored.
Although numerous trials have evaluated novel therapies for
the treatment of relapsed/refractory PTCL, prospective phase III
trials are lacking. The absence of comparative trials hinders making
impartial clinical recommendations for individual treatment
regimens.
Development of novel therapies necessitates the development
of paradigms for combining these agents, to improve response
rates and durability of responses. Romidepsin may be particularly
suitable for combination therapy because of its favorable toxicity
proﬁle compared with pralatrexate. A phase III trial assessing romi-
depsin combined with CHOP versus monotherapy is currently
ongoing. Brentuximab vedotin has shown to be very effective in
CD30+ ALCL and may also prove useful for the treatment of other
T-cell lymphomas. It is of great interest whether brentuximab
vedotin adds to the effect of other drugs or regimens: a phase II
clinical trial of brentuximab vedotin in combination with CHOP
has been completed recently and several studies are currently
underway, including a large international phase III trial comparing
CHOP versus CHP plus brentuximab vedotin. The combination of
alemtuzumab with other drugs also warrants further exploration:
two international phase III trials (ACT-1 and ACT-2) comparing
CHOP versus CHOP plus alemtuzumab have just completed enroll-
ment. Bendamustine is also amenable for use in numerous combi-
nation regimens.
Having several new agents available with demonstrated activity
in refractory T-cell lymphoma will provide additional therapeutic
approaches for patients, lead to development of new combination
approaches, and improve treatment options and long-term out-
comes for these difﬁcult-to-treat patients.
Additional studies are needed to determine the relative value of
these novel therapies, as monotherapy or in combination, in the
different subtypes of PTCL and to continue to evaluate the role of
other treatment modalities, including SCT, conventional chemo-
therapy, and radiotherapy for optimizing responses and long-term
outcomes in PTCL. The development of new and effective treat-
ment strategies will improve overall outcomes in patients with
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